Meriofert (Luteinising Hormone (Human), Follicle-Stimulating Hormone)

The hormones in Meriofert bind to LH and FSH receptors on ovarian or testicular cells. This activates intracellular pathways that increase steroid hormone production and promote gamete development, leading to follicle growth, ovulation, or spermatogenesis required for fertility.

The dose of Meriofert is individualized. The prescribing clinician determines the amount, frequency, and duration based on the patient’s specific condition, response to therapy, and treatment protocol.

Meriofert is intended for use in patients seeking to achieve pregnancy and is not administered during an established pregnancy. Safety during breastfeeding has not been established, and the medication should only be used under medical supervision.

To order Meriofert, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed) and any required import documentation.

Meriofert provides both LH and FSH activity in a single preparation, whereas some alternatives contain only one hormone and require separate administration. This combined approach can simplify dosing schedules and may improve follicular response in certain protocols, but the choice depends on the clinician’s assessment of the patient’s needs.

Meriofert must be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. Do not use the product if it has been exposed to temperatures outside the recommended range.

Meriofert is supplied as an injectable solution for intramuscular or subcutaneous injection. Administration is performed by a qualified healthcare professional following aseptic technique and the dosing schedule prescribed by the treating physician.

The most serious risks include ovarian hyperstimulation syndrome, which can be severe and lead to complications such as fluid accumulation, thrombosis, or ovarian torsion, and the possibility of multiple pregnancy. Prompt medical attention is required if severe abdominal pain, rapid weight gain, or shortness of breath occur.

Meriofert should not be used in patients with uncontrolled thyroid disease, active ovarian cysts, untreated pituitary tumors, or a known hypersensitivity to human gonadotropins. It is also contraindicated in individuals with a high risk of thromboembolic events unless carefully monitored.